Point72 Asset Management L.P. Acquires 159,988 Shares of Qiagen NV (NYSE:QGEN)

Share on StockTwits

Point72 Asset Management L.P. boosted its holdings in shares of Qiagen NV (NYSE:QGEN) by 1,385.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 171,532 shares of the company’s stock after acquiring an additional 159,988 shares during the period. Point72 Asset Management L.P. owned about 0.08% of Qiagen worth $5,655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. M&T Bank Corp boosted its holdings in shares of Qiagen by 45.4% in the 2nd quarter. M&T Bank Corp now owns 8,230 shares of the company’s stock valued at $333,000 after buying an additional 2,568 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Qiagen by 28.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,195,033 shares of the company’s stock valued at $89,011,000 after buying an additional 487,844 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Qiagen by 17.9% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,036 shares of the company’s stock valued at $772,000 after buying an additional 2,893 shares in the last quarter. Mackenzie Financial Corp bought a new stake in shares of Qiagen in the 2nd quarter valued at about $11,244,000. Finally, Huntington National Bank boosted its holdings in shares of Qiagen by 33.3% in the 3rd quarter. Huntington National Bank now owns 1,568 shares of the company’s stock valued at $52,000 after buying an additional 392 shares in the last quarter. Institutional investors own 62.69% of the company’s stock.

QGEN opened at $42.80 on Monday. Qiagen NV has a 12-month low of $25.04 and a 12-month high of $43.04. The company has a current ratio of 2.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $9.62 billion, a PE ratio of 31.94, a P/E/G ratio of 3.19 and a beta of 0.83. The firm has a 50 day moving average of $33.06 and a two-hundred day moving average of $35.89.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.01. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The company had revenue of $382.70 million during the quarter, compared to analyst estimates of $382.98 million. During the same period last year, the firm posted $0.35 EPS. Qiagen’s revenue for the quarter was up 1.3% compared to the same quarter last year. As a group, analysts predict that Qiagen NV will post 1.4 EPS for the current fiscal year.

A number of analysts have recently weighed in on QGEN shares. ValuEngine cut shares of Qiagen from a “buy” rating to a “hold” rating in a report on Tuesday, August 20th. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating in a research note on Thursday, October 17th. Deutsche Bank cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Zacks Investment Research upgraded shares of Qiagen from a “sell” rating to a “hold” rating and set a $32.00 target price for the company in a research note on Monday, November 4th. Finally, Kepler Capital Markets upgraded shares of Qiagen from a “reduce” rating to a “hold” rating in a research note on Thursday, November 14th. Ten investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $36.78.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Read More: Cost of Debt

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.